<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862651</url>
  </required_header>
  <id_info>
    <org_study_id>MB11-2018</org_study_id>
    <nct_id>NCT03862651</nct_id>
  </id_info>
  <brief_title>Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)</brief_title>
  <official_title>MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Santa Croce-Carle Cuneo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Santa Croce-Carle Cuneo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting
      bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12
      months from coronary stent implantation. It seeks to determine if initiation of a prolonged
      cangrelor infusion maintains effective platelet inhibition after discontinuation of P2Y12 and
      whether a cangrelor infusion before cardiac and non cardiac procedures is safe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled study enrolling patients with
      coronary stent, still on DAPT, undergoing cardiac and non cardiac surgery within 12 months
      from coronary stent implantation.

      The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting
      bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12
      months from coronary stent implantation. It seeks to determine if initiation of a prolonged
      cangrelor infusion maintains effective platelet inhibition after discontinuation of P2Y12 and
      whether a cangrelor infusion before cardiac and non cardiac procedures is safe.

      The primary efficacy objective of this study is to demonstrate that a cangrelor infusion will
      maintain levels of residual platelet reactivity (PRU &lt; 208) as measured by Accriva VerifyNow®
      P2Y12 assay.

      The main safety objective is to demonstrate that patients receiving cangrelor infusion before
      cardiac and non cardiac surgery have an acceptable safety profile and can undergo surgery
      without excessive bleeding peri-operatively.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LEVEL OF RESIDUAL PLATELET REACTIVITY</measure>
    <time_frame>1-2 hours</time_frame>
    <description>Accriva VerifyNow P2Y12 assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ischemic and hemorrhagic endpoints</measure>
    <time_frame>30 days</time_frame>
    <description>Bleeding Academic Research Consortium (BARC) grade &gt; 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Platelet Aggregation Inhibitors</condition>
  <arm_group>
    <arm_group_label>Cangrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cangrelor, 0.75 μg/Kg/min, a cangrelor infusion will be started in addition to SOC when the P2Y12 inhibitor has been discontinued after the need for surgery has been determined. The infusions (cangrelor or matching placebo) will continue throughout the pre-operative period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will receive only standard of care, in which the P2Y12 inhibitor is discontinued after the need for surgery has been determined and a placebo infusion is administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cangrelor</intervention_name>
    <description>Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.</description>
    <arm_group_label>Cangrelor</arm_group_label>
    <other_name>KENGREXAL® (cangrelor)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent before initiation of any study related procedures.

          2. Be ≥ 18 years of age.

          3. Have received any dose of a P2Y12 inhibitor (clopidogrel, ticlopidine, prasugrel, or
             ticagrelor) at any dose within at least 48 hours prior to randomization.

          4. Patients undergoing non deferrable cardiac or non cardiac surgery which requires
             discontinuation of P2Y12 inhibitor due to a significant bleeding risk.

        Exclusion Criteria:

          1. Confirmed of suspected pregnancy (if woman of child-bearing potential) or lactating
             females

          2. Active bleeding with evident contraindications to DAPT

          3. Patients requiring oral anticoagulant therapy

          4. PCI within 1 month

          5. Intracranial neoplasm or history of intracranial surgery

          6. History of bleeding diathesis

          7. Thrombocytopenia (platelet count of less than 100,000/µL)

          8. Known International Normalized Ratio (INR) greater than 1.5 at screening.

          9. Requirement for dialysis treatment (hemodialysis or peritoneal)

         10. Estimated Glomeular filtration rate eGFR &lt;30 ml/min

         11. Administration of abciximab within 24 hours of randomization or administration of
             eptifibitide or tirofiban within 12 hours of randomization

         12. Plans to continue oral anticoagulant or P2Y12 inhibitors or cangrelor in the
             pre-operative period

         13. Refusal to receive blood transfusion

         14. Receipt of fibrinolytic therapy in the 12 hours preceding randomization

         15. Allergy, hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or
             microcrystalline cellulose

         16. High likelihood of being unavailable for follow-up

         17. Participation in other clinical research studies involving the evaluation of other
             investigational drugs or devices within 30 days of randomization

         18. Any disease or condition which, in the judgment of the investigator, would place the
             patient at undue risk by being enrolled in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25. Review. Erratum in: Circulation. 2017 Mar 7;135(10 ):e646. Circulation. 2017 Sep 5;136(10 ):e196.</citation>
    <PMID>28122885</PMID>
  </reference>
  <reference>
    <citation>Moschovitis A, Cook S, Meier B. Percutaneous coronary interventions in Europe in 2006. EuroIntervention. 2010 Jun;6(2):189-94. doi: 10.4244/.</citation>
    <PMID>20562067</PMID>
  </reference>
  <reference>
    <citation>Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol. 2007 Jun 5;49(22):2145-50. Epub 2007 May 23. Review.</citation>
    <PMID>17543633</PMID>
  </reference>
  <reference>
    <citation>Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun M, Feringa HH, Hoeks SE, Poldermans D. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol. 2007 Jan 2;49(1):122-4. Epub 2006 Dec 18.</citation>
    <PMID>17207733</PMID>
  </reference>
  <reference>
    <citation>Albaladejo P, Marret E, Samama CM, Collet JP, Abhay K, Loutrel O, Charbonneau H, Jaber S, Thoret S, Bosson JL, Piriou V. Non-cardiac surgery in patients with coronary stents: the RECO study. Heart. 2011 Oct;97(19):1566-72. doi: 10.1136/hrt.2011.224519. Epub 2011 Jul 26.</citation>
    <PMID>21791513</PMID>
  </reference>
  <reference>
    <citation>Rossini R, Musumeci G, Capodanno D, Lettieri C, Limbruno U, Tarantini G, Russo N, Calabria P, Romano M, Inashvili A, Sirbu V, Guagliumi G, Valsecchi O, Senni M, Gavazzi A, Angiolillo DJ. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost. 2015 Feb;113(2):272-82. doi: 10.1160/TH14-05-0436. Epub 2014 Oct 2.</citation>
    <PMID>25274620</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Santa Croce-Carle Cuneo</investigator_affiliation>
    <investigator_full_name>ROBERTA ROSSINI</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>aNtiplatElet Therapy</keyword>
  <keyword>cangrelor</keyword>
  <keyword>randomized</keyword>
  <keyword>DAPT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cangrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

